The Health Policy Exchange
MAY 7, 2013
To the ACA's detractors, Medicaid expansion is a hostile government takeover that must be opposed in principle, regardless of potential benefits of an infusion of federal dollars. In fiscal year 2011, Medicaid spending totaled $414 billion, with two-thirds going to services for disabled elderly persons.
FDA Law
NOVEMBER 6, 2022
2011), here , and United States v. Rather, Pfizer argues, the AKS focuses on “corrupt transactions,” such as the specific examples of “kickback, bribe, or rebate” that Congress provided. Borrasi, 639 F.3d 3d 774 (7th Cir. Greber, 760 F.2d 2d 68, 71 (3d Cir.), denied, 474 U.S. 988 (1985), here ).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Law
MAY 3, 2021
Recent Department of Justice (“DOJ”) press releases continue to show evidence of reported registrant civil settlements with the Government alleging recordkeeping and reporting deficiencies. Part 1 provides background and explains the scope of DEA cyclic and on-site inspections. 39,318 , 39,324 (July 6, 2011). Background.
FDA Law
JULY 24, 2023
Its main argument is that Congress included only two exceptions to FDA’s restriction barring FDA from granting new approvals during the ODE period: the inability to provide sufficient quantities of a drug and consent from the ODE holder.
FDA Law
MAY 3, 2021
Recent Department of Justice (“DOJ”) press releases continue to show evidence of reported registrant civil settlements with the Government alleging recordkeeping and reporting deficiencies. Part 1 provides background and explains the scope of DEA cyclic and on-site inspections. 39,318 , 39,324 (July 6, 2011). Background.
Medical Xpress
JUNE 16, 2025
This region governs essential behaviors like the circadian clock, sleep, energy balance , and feeding. The content is provided for information purposes only. But technical limitations have made it hard to understand how neurons in this area form functional circuits." Your feedback is important to us.
FDA Law
MAY 11, 2023
government in the now-infamous (at least in FDA circles) Teva v. In the brief , the Government takes a strong position, stating “[t]he court of appeals’ holding that respondents presented sufficient evidence of petitioner’s intent to induce infringement is erroneous and warrants this Court’s review.” GSK skinny label case , the U.S.
Expert insights. Personalized for you.
130 
Let's personalize your content